Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BTX-9341 |
Synonyms | |
Therapy Description |
BTX-9341 is a degrader of CDK4/6, which decreases Rb1 protein phosphorylation and potentially induces cell cycle arrest and tumor growth inhibition (Cancer Res (2024) 84 (9_Supplement): PO5-05-02). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BTX-9341 | BTX9341|BTX 9341 | BTX-9341 is a degrader of CDK4/6, which decreases Rb1 protein phosphorylation and potentially induces cell cycle arrest and tumor growth inhibition (Cancer Res (2024) 84 (9_Supplement): PO5-05-02). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06515470 | Phase I | BTX-9341 BTX-9341 + Fulvestrant | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer | Recruiting | USA | 0 |